Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current

• US 10,357,458 B2
• Filed: 05/17/2017
• Issued: 07/23/2019
• Est. Priority Date: 06/03/2011
• Status: Active Grant

• Current Assignee: SignPath Pharma, Inc.
• Original Assignee: SignPath Pharma, Inc.
• Inventors: Helson, Lawrence
• Primary Examiner(s): Roney, Celeste A
• Application Number:
  US15/597,411
• Publication Number:
  US 20170246110A1
• Time in Patent Office: 797 Days
• Field of Search: None
• CPC Class Codes: A61K 31/12 Ketones
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/4545 containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: Y10S 977/773 Nanoparticle, i.e. structure having three dimensions of 100 nm or less
• CPC Class Codes: Y10S 977/906 Drug delivery
• CPC Class Codes: Y10S 977/907 Liposome

Abstract

Compositions and methods for the treatment of drug-induced long QT syndrome and other cardiac channelopathies are disclosed herein. The compositions and methods of the present invention comprise binding one or more QT prolonging drugs with a liposome prior to parenteral (intravenous or subcutaneous) administration, or administration of an empty liposome prior to or concomitantly with therapeutic agents known to have a high risk of QT prolongation, or immediately following an envenomation. The results presented show an abrogation of the adverse effects of QT prolonging drugs in a dose-dependent manner by the compositions of the present invention.

Claims

1. A composition for treating channelopathies or a cardiopathy caused by the administration of one or more drugs in a human or animal subject consisting of:

a combination of one or more pharmacologically active agents that cause a cardiopathy in the subject; and

one or more empty liposomes administered prior to, concomitantly, or after administration of the pharmacologically active agent effective to reduce or eliminate the cardiopathy caused by the active agent, wherein the composition is dispersed in a pharmaceutically acceptable medium and the cardiopathy is selected from long QT syndrome (LQTS), atrial flutter, atrial fibrillation, ventricular tachycardia, sinus bradycardia, sinus tachycardia, atrial tachycardia, atrial fibrillation, atrial flutter, atrioventricular nodal block, atrioventricular node reentry tachycardia, atrioventricular reciprocating tachycardia, ventricular tachycardia, ventricular fibrillation, or any combinations thereof wherein the one or more active agents consists of Aloxi or palonasitron HCL, Amiodarone, Arsenic trioxide, Astemizole, Bepridil, Chloroquine-Chlorpheniramine, Chlorpromazine, Cisapride, Celaxa, Clarithromycin, Erythromycin, Curcumin, Disopyramide, Dofetilide, Domperidone, Doxorubicin, Dronedarone, Droperidol, Grepafloxacin, Haldol, Haloperidol, Halofantrine, Ibutilide, Levomethadyl, Lidoflazine, Loratidine, Lovostatin, Mesoridazone, Methadone, Methanesulphonanilide (E-4031), Moxifloxacin, Pentamadine, Pimozide, Prenylamine, Probucol, Procainamide, Propafenone, Pyrilamine, Quinidine, Terfenidine, Sertindole, Sotalol, Sparfloxacin, or Thioridazine.

2. The composition of claim 1, wherein the composition is used for the treatment of the LQTS induced by administration of one or more drugs used in the treatment of cardiac or non-cardiac related diseases.

3. The composition of claim 1, wherein the composition is adapted for parenteral or oral administration.

4. The composition of claim 1, wherein the active agent and the liposomes may be bound or conjugated together.

5. The composition of claim 1, wherein the liposomes comprise anionic, cationic, or neutral liposomes.

6. The composition of claim 1, wherein the liposomes comprise a lipid or a phospholipid wall, wherein the lipids or the phospholipids are selected from the group consisting of phosphatidylcholine, lysolecithin, lysophosphatidylethanol-amine, phosphatidylserine, phosphatidylinositol, sphingomyelin, phosphatidylethanolamine, cardiolipin, phosphatidic acid, cerebrosides, dicetylphosphate, phosphatidylcholine, and dipalmitoyl-phosphatidylglycerol, stearylamine, dodecylamine, hexadecyl-amine, acetyl palmitate, glycerol ricinoleate, hexadecyl sterate, isopropyl myristate, amphoteric acrylic polymers, fatty acid, fatty acid amides, cholesterol, cholesterol ester, diacylglycerol, and diacylglycerolsuccinate.

7. The composition of claim 1, wherein the liposomes are spherical liposomes with a diameter ranging from 10 nm-200 nm.

8. A composition for treating a cardiopathy in a human or animal subject consisting of:

a therapeutically active agent or a drug that causes a cardiopathy; and

one or more liposomes administered prior to, concomitantly, or after administration of the therapeutically active agent or the drug effective to reduce the cardiopathy caused by the one or more drugs, wherein the composition is dispersed in a pharmaceutically acceptable medium and the therapeutically active agent or a drug is not encapsulated by the liposomes, and wherein the cardiopathy is selected from the group consisting of long QT syndrome (LQTS), atrial flutter, atrial fibrillation, ventricular tachycardia, sinus bradycardia, sinus tachycardia, atrial tachycardia, atrial fibrillation, atrial flutter, atrioventricular nodal block, atrioventricular node reentry tachycardia, atrioventricular reciprocating tachycardia, ventricular tachycardia, ventricular fibrillation, or any combinations thereof and wherein the therapeutically active agent or drug consists of Aloxi or palonasitron HCl, Amiodarone, Arsenic trioxide, Astemizole, Bepridil, Chloroquine-Chlorpheniramine, Chlorpromazine, Cisapride, Celaxa, Clarithromycin, Erythromycin, Disopyramide, Dofetilide, Domperidone, Doxorubicin, Dronedarone, Droperidol, Grepafloxacin, Haldol, Haloperidol, Halofantrine, Ibutilide, Levomethadyl, Lidoflazine, Loratidine, Lovostatin, Mesoridazone, Methadone, Methanesulphonanilide (E-4031), Moxifloxacin, Pentamadine, Pimozide, Prenylamine, Probucol, Procainamide, Propafenone, Pyrilamine, Quinidine, Terfenidine, Sertindole, Sotalol, Sparfloxacin, or Thioridazine.

9. The composition of claim 8, wherein the therapeutically active agent or a drug is used in a treatment of one or more cardiac or non-cardiac diseases in the human or animal subject.

10. The composition of claim 8, wherein the therapeutically active agent or a drug is selected from one or more drug classes comprising β

-blockers, sodium channel blockers, potassium supplements, potassium channel openers, hERG current enhancers, calcium channel blockers, agents for correcting trafficking defects, gap junction coupling enhancers, or any combinations thereof.

11. The composition of claim 8, wherein the composition is adapted for parenteral or oral administration.

12. The composition of claim 8, wherein the liposomes comprise anionic, cationic, or neutral liposomes comprising a lipid or a phospholipid wall, wherein the lipids or the phospholipids are selected from the group consisting of phosphatidylcholine, lysolecithin, lysophosphatidylethanol-amine, phosphatidylserine, phosphatidylinositol, sphingomyelin, phosphatidylethanolamine, cardiolipin, phosphatidic acid, cerebrosides, dicetylphosphate, phosphatidylcholine, and dipalmitoyl-phosphatidylglycerol, stearylamine, dodecylamine, hexadecyl-amine, acetyl palmitate, glycerol ricinoleate, hexadecyl sterate, isopropyl myristate, amphoteric acrylic polymers, fatty acid, fatty acid amides, cholesterol, cholesterol ester, diacylglycerol, and diacylglycerol succinate.